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Novel Bullet for Dyslipidemia and Cardiovascular 
Disease in the Horizon: Does Genetics Contribute to 
the Blueprint?
Anwar Santoso
The development of novel therapy for dyslipidemia and cardiovascular diseases (CVD) had been constrained by some challenges, and several recent approaches 
have failed for lack of efficacy. Progress had been 
made by a single, greatest contribution from statins 
in reducing the risk of CVD. However, the burden of 
CVD and residual risk remains quite high, and new 
pathways to prevent and treat the diseases are still 
needed. Despite this clear unmet need, nevertheless 
many research institutions have begun to withdraw 
their efforts in discovering ‘the new bullet’ for this 
prevalent diseases1.
Though statins are effective drugs, their utilization 
is sometimes fraught with issues, such as failure of 
adequate lipid control in approximately 30% of cases 
and intolerance in selected subjects, and also new-
onset diabetes issue. Also, the limited efficacy of other 
drugs such as bile acid sequestrants, fibrates and niacin 
has urged the search for other novel molecules with 
better efficacy and safety. 2As examples, within the past 
several years, large clinical trials of lipid-altering drugs 
(niacin)3,4, as well as new therapeutic options such as 
cholesteryl ester transfer protein (CETP) inhibitor 
(dalcetrapib)5, secreted phospholipase A2 (sPLA2) 
inhibitor (varespladib)6, and lipoprotein-associated 
phospholipase A2 (LpPLA2) inhibitor (darapladib)7 
failed to convey important clinical benefits in reducing 
CVD outcome. 
Regrettably, animal models of atherosclerosis 
have not reliably convinced at predicting new anti-
atherosclerotic therapies that would be effective in 
human. Further, non-invasive atherosclerosis imaging 
approaches had not been predictive of clinical outcomes 
in response to therapy. Dalcetrapib, varespladib and 
darapladib were all shown, to some extent, to get positive 
and beneficial effects in animal models and in imaging 
studies in humans as well, but unfortunately failed in 
large CVD outcome trials.    
In contrast, human genetics can bring forth much 
greater confidence that a therapeutic targeted to a 
particular pathway will show clinical benefit in reducing 
major CVD events8. A particular example of this proof 
of concept is the report about proprotein convertase 
subtilisin/kexin type 9 (PCSK9). PCSK9 is a serine 
protease involved in the degradation of the LDL receptor. 
It binds to the LDL receptor present on the surface of 
the cell viaclathrin-coated pits and leads to internalization 
of LDL receptor, leading to degradation and resultant 
increase in the concentration of LDL cholesterol.9A 
specific mutation in PCSK9 gene namely D374Y was 
found to cause a gain-of-function, resulting in increased 
binding of PCSK9 to the LDL receptor and resultant 
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degradation. The findings related to inhibition of PCSK9 
are burgeoning as an attractive target for reducing LDL-C 
in both dyslipidemia and CVD.10,11
Loss of function mutations in the PCSK9 gene 
were associated with very low levels of LDL-C and, 
more importantly, substantial risk reduction for 
coronary artery disease. 12This influential finding 
contributes to a great confidence that pharmaco-
logic inhibition of PCSK9 would not only decrease 
LDL-C levels, but also reduce the risk of CVD. In 
the future, we would have unequivocal evidence that 
inhibition of PCSK9 notably reduces LDL-C in hu-
man. 13Although studies aimed to prove that PCSK9 
inhibition improving risk of CVD are still ongoing, 
there is a high level of hope and confidence based on 
the human genetics data. 
Alternatively, plasma triglycerides (TG) are an 
interesting case in point. There are ample observa-
tional epidemiologic data showing that TG levels is 
positively associated with increased CVD risk, but 
there has been uncertainty about the causal nature 
of this association. However, a recent large study 
comprehensively addressed the genetic relationships 
and found that variants associated with TG concen-
tration were associated with CVD risk even after 
being adjusted for the effects of these variants on 
LDL-C and HDL-C.1This suggests that certain pro-
teins regulating TG metabolism could be potential 
targets for therapy. For example, a gain-of-function 
variant in lipoprotein lipase (LPL) is associated with 
reduced TG concentration (as well as increased 
HDL-C) and reduced risk of CVD, indicating that 
increased LPL activity may be atheroprotective. 
LPL also has several natural inhibitors, including 
apolipoprotein C-III (apoC-III and gene APOC3). 
A loss-of-function nonsense variant in APOC3 is 
associated with reduced TG (and increased HDL-C) 
as well as reduced coronary atherosclerosis. 14This 
suggests that APOC3 may be an attractive target for 
pharmacologic inhibition. 
While it may not be a straightforward proposition 
to take away statins from their current position as 
a cholesterol reducing agent and a drug to improve 
CVD, our new comprehension of this diseases and 
appropriate harnessing of resources using sound and 
robust technology could make rapid in roads in our 
pursuit of the ideal anti-dyslipidemic and CVD bullets 
in the horizon.2
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